The Pharmaceutical Processing Equipment Market is projected to grow at a CAGR of 4.2% from 2022 to 2029 and is expected to reach $12.85 billion by 2029. Pharmaceutical processing includes a range of unit operations such as blending, milling, granulation, tablet pressing, coating, and filling, depending on the mode of delivery. With the growing adoption of continuous manufacturing and the rising number of novel therapies in clinical development, pharmaceutical equipment is becoming a central inflection point for developing new therapies. New types of therapies entering the clinical pipeline and orphan drug designation are driving the technological innovations in pharmaceutical processing. Apart from the technological innovations, the growing pharmaceutical market, a trend of flexible manufacturing, and rising contract manufacturing of pharmaceuticals are the factors driving the pharmaceutical processing equipment market.
Pharmaceutical manufacturing is witnessing a rapid transition. Prevalent trends in pharmaceutical manufacturing include low volume production, an increase in the pharmaceutical manufacturing process, and the growing adoption of digital and single-use technologies.
COVID-19 Impact Assessment
The COVID-19 pandemic has positively impacted the pharmaceutical processing equipment market. It has increased the demand for therapeutics for fighting the COVID-19 outbreak. Several pharmaceutical manufacturers are expanding their manufacturing facilities due to the significant demand for vaccines and medicines for the novel coronavirus. Pharmaceutical manufacturing is also outsourcing operations to meet the growing market demand. This strategy is expected to improve the demand for new processing equipment.
Pharmaceutical manufacturing was lagging in various countries because of the disruption created in the supply chain due to the COVID-19 pandemic. To tackle this situation, the public organizations of various countries have focused on decreasing the dependency on imports by domestic pharmaceutical manufacturing. The reshoring manufacturing opportunities would be developed in Europe, the U.S., and Japan. Additionally, the government of these countries are also likely to develop preferred access regulations mandating the local supply of essential API and drugs using available financial grants.
Growing Trend of Contract Manufacturing in the Pharmaceutical Sector
Pharmaceutical companies face challenges such as controlling manufacturing costs and navigating stringent regulatory approval processes. The high consumption of small molecules for treating different diseases, the emergence of advanced technologies in the manufacture of finished dosage formulations, patent expirations of small molecules, and the rising demand for generics support the growth of contract manufacturing in the pharmaceutical sector. Small pharmaceutical companies also lack well-equipped infrastructure, advanced technologies, and high containment capabilities to produce pharmaceuticals, due to which they prefer outsourcing manufacturing operations to keep initial investments low. As manufacturing processes are becoming increasingly complex and stringent regulations are being imposed, pharmaceutical companies are developing long-term contracts with Contract Manufacturing Organizations (CMOs).
Pricing pressures in the pharmaceutical industry have driven pharmaceutical CMOs to establish operations in India, China, Singapore, South Korea, and Malaysia. The Government of India offers soft loans to support manufacturing facilities for CMOs in India. According to the Indian Drug Manufacturers’ Association (IDMA), India has the edge over other countries in producing basic medicinal products due to the availability of cost-effective resources, WHO-GMP-approved production facilities, and rapidly developing infrastructure. The CMOs that offshore operations to India can lower production costs by 40%.
Thus, the pricing pressures prevalent in the pharmaceutical industry and increased pharmaceutical production are expected to increase the focus on contract manufacturing.
Key Findings in the Global Pharmaceutical Processing Equipment Market Study
By Mode of Delivery, in 2022 Oral Formulations Segment is Estimated to Generate the Largest Proportion of Revenue in the Pharmaceutical Processing Equipment Market
Based on the mode of delivery, the pharmaceutical processing equipment market segment is divided into oral, parenteral, topical, and other modes of delivery. Oral formulations is the most preferred mode of delivery, owing to its ease in consumption, convenience, safety, and cost-effectiveness. Furthermore, patients’ compliance is higher with this mode than with other delivery modes. The oral dosage forms also offer ease in large-scale manufacturing. Thus, based on these factors, the preference for oral formulations is likely to continue to increase during the forecast period.
North America: Largest Revenue Contributing Regional Market
Reshoring of pharmaceutical manufacturing in the U.S., expansion of manufacturing facilities, and agreements between pharmaceutical companies and CMOs to increase the availability of pharmaceuticals are the key factors contributing to the largest revenue share in North America. Additionally, an increase in the government funding to develop COVID-19-related-therapies is also driving the demand for innovative technologies in pharmaceutical processing.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past three years. The market players profiled in the global pharmaceutical processing equipment market report are ACG (India), Cadmach Machinery Company Private Limited (India), GEA GROUP (Germany), Sainty Co. (China), Syntegon Technology GmbH (Germany), Freund Corporation (Japan), ACIC Pharmaceuticals Inc. (Canada), Bausch+Ströbel Maschinenfabrik Ilshofen GmbH + Co. KG (Germany), Fette Compacting GmbH (Germany), IDEX Corporation (U.S.), Kevin Process Technologies Private Limited (India), KIKUSUI SEISAKUSHO LTD. (Japan), KORSCH AG (Germany), MAQUINARIA INDUSTRIAL DARA, SL (Spain), and Marchesini Group S.p.A. (Italy).
Scope of the Report:
Pharmaceutical Processing Equipment Market, by Mode of Delivery
- Oral Formulations
- Oral Solid Dosages
- Blending Equipment
- Fluidized Bed Machine
- Milling Equipment
- Compression/Press Equipment
- Capsule Making Equipment
- Capsule Filling Equipment
- Other Processing Equipment
(Other processing equipment for oral solid dosages majorly includes inspection machines, dust extractors, and polishing machines)
- Oral Liquid Dosages
- Sugar Charging/Transfer Systems
- Preparation Vessels, Melting Vessels, and Storage Tanks
- Stirrers and Homogenizers
- Filtration Units
- Others
(Other processing equipment for oral liquid dosages majorly includes transfer pumps and interconnect pipelines)
- Parenteral formulations
- Mixing Equipment, Preparation Tank, and Other Containers
- Process Systems (SVP, LVP)
- Filtration Units
- Sterilization Tunnels
- Clean-in-Place (CIP) and Steam-in-Place (SIP) System
- Aseptic Inspection Systems
- Other Processing Equipment
(Other processing equipment for parenteral formulations majorly include debagging machine, nest unpackers, tray unpackers, tray loading, buffering, and barrier systems)
- Topical Formulation
- Planetary and Homogenizer Mixer
- Preparation Vessels, Reactors, and Storage Tanks
- Colloid Mills
- Agitator–Stirrer
- Other Processing Equipment
(Other processing equipment for topical formulations majorly include milling equipment and sifters)
- Other Formulations
(Other formulations majorly include trans-mucosal and inhalation drugs)
Pharmaceutical Processing Equipment Market, by Geography
- North America
- Europe
- Switzerland
- Italy
- Germany
- U.K.
- France
- Ireland
- Spain
- Denmark
- Belgium
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa (MEA)
Key Questions Answered in the Report:
